NCT06171490View on ClinicalTrials.gov

Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of NP2, NP2-4mg and NP2-6mg, Compared to Nicotine Lozenge 4mg (Loz-4mg) and Nicotine Gum 4mg (Gum-4mg)

NACompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 20, 2023

Primary Completion Date

January 14, 2024

Study Completion Date

March 20, 2024

Conditions
Tobacco Use
Interventions
OTHER

NP2-4mg

NP2-4 mg is a new product containing tobacco-derived nicotine.

OTHER

NP2-6 mg

NP2-6 mg is a new product containing tobacco-derived nicotine.

OTHER

Loz-4mg

The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.

OTHER

Gum-4mg

The Gum-4mg reference product is a commercially available 4mg nicotine gum.

Trial Locations (2)

M1S 3V6

Pharma Medica Research Inc., Toronto

G1P 0A2

Syneos Health Clinique Inc., Québec

All Listed Sponsors
lead

Philip Morris Products S.A.

INDUSTRY

NCT06171490 - Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of NP2, NP2-4mg and NP2-6mg, Compared to Nicotine Lozenge 4mg (Loz-4mg) and Nicotine Gum 4mg (Gum-4mg) | Biotech Hunter | Biotech Hunter